Back to Gene
CCM2 gene
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Gene

CCM2 gene

The CCM2 gene provides instructions for making the malcavernin protein, which is essential for maintaining the structural integrity of blood vessels.

Normal Function

The CCM2 gene provides instructions for making a protein called malcavernin, which strengthens the interactions between cells that form blood vessels and limits leakage from the vessels. Malcavernin interacts with a number of other proteins to form a complex that is found in the junctions that connect neighboring cells. As part of this complex, malcavernin helps turn off (suppress) a signaling molecule known as RhoA-GTPase. This molecule plays a role in regulating the actin cytoskeleton, which is a network of fibers that makes up the cell's structural framework. When turned on, RhoA-GTPase stimulates the formation of actin fibers, which has been linked to weakened junctions between cells and increased leakage from blood vessels.

Malcavernin is also involved in a process called angiogenesis, which is the formation of new blood vessels.

Health Conditions Related to Genetic Changes

Cerebral cavernous malformation

Dozens of mutations in the CCM2 gene have been identified in families with cerebral cavernous malformations, which are collections of blood vessels in the brain that are weak and prone to leakage. Most of these mutations result in an abnormally short or malformed malcavernin protein that does not function. A shortage of this protein likely impairs the function of the complex. As a result, RhoA-GTPase signaling is turned on abnormally, weakening cellular junctions and increasing the permeability of blood vessel walls. The increased leakage into the brain can cause health problems such as headaches, seizures, and bleeding in the brain (cerebral hemorrhage) in some people with cerebral cavernous malformations.

Mutations in the CCM2 gene are involved in approximately 15 percent of all familial cerebral cavernous malformation cases.

Frequently Asked Questions

Sudden severe headache, new onset seizures, focal neurological deficits (such as weakness or vision changes), or any rapid worsening of existing symptoms should be evaluated immediately, as they may indicate hemorrhage from a cavernous malformation.
While no lifestyle modification eliminates risk, avoiding anticoagulant medications unless medically necessary, controlling blood pressure, and abstaining from high‑impact contact sports may lower the chance of lesion rupture.
If a first‑degree relative has a confirmed CCM2 mutation, predictive genetic testing is recommended to determine your carrier status. Testing is done with a blood sample, and results can guide surveillance MRI schedules and inform family planning decisions.
Most clinicians recommend an MRI with susceptibility‑weighted imaging every 1–2 years, or sooner if new symptoms appear, to monitor for the development or growth of cavernous lesions.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

kontakt@hittavard.se

Ⓒ 2024. Alla rättigheter förbehålls av juxt ab